SYENSQO 66.500 € (+1,60 %) AEDIFICA 71.550 € (+0,63 %) AB INBEV 71.900 € (+0,67 %) ACKERMANS V.HAAREN 274.000 € (+0,51 %) GBL 81.000 € (+1,12 %) ARGENX SE 701.000 € (-0,74 %) COLRUYT 33.460 € (+0,36 %) GIMV 49.500 € (+0,30 %) MATERIALISE 5.100 € (+4,08 %) COFINIMMO 84.050 € (+1,57 %) WDP 22.020 € (-2,05 %) AZELIS GROUP 10.310 € (-0,48 %) VASTNED 29.500 € (0,00 %) KBC 112.600 € (+2,04 %) SOLVAY 26.000 € (+2,04 %) LOTUS BAKERIES 10 840.000 € (-0,91 %) KBC ANCORA 79.200 € (+1,93 %) FAGRON 25.000 € (0,00 %) ONTEX GROUP 2.660 € (-3,27 %) TESSENDERLO 21.400 € (-0,23 %) ECONOCOM GROUP 1.550 € (+3,33 %) NYXOAH 2.450 € (+1,24 %) IMMOBEL 21.800 € (0,00 %) HOME INVEST BE. 18.940 € (-0,32 %) DEME GROUP 187.000 € (-0,85 %) TUBIZE-FIN 207.800 € (0,00 %) XIOR 27.300 € (+1,30 %) CENERGY 24.020 € (+0,08 %) BANQUP GROUP 2.450 € (+3,38 %) BARCO 9.145 € (+1,55 %) UMICORE 26.180 € (+5,74 %) QRF 11.650 € (+2,19 %) CARE PROPERTY INV. 13.180 € (-0,15 %) UCB 242.000 € (+0,46 %) VAN DE VELDE 30.700 € (+0,66 %) SOFINA 223.800 € (+0,54 %) VIOHALCO 19.060 € (-2,16 %) MELEXIS 81.450 € (+6,12 %) WAREHOUSES ESTATES 40.000 € (-0,25 %) TITAN S.A. 47.860 € (+1,27 %) JENSEN-GROUP 76.400 € (-0,78 %) CIE BOIS SAUVAGE 313.000 € (-1,26 %) FLUXYS BELGIUM D 19.850 € (-1,73 %) PROXIMUS 6.900 € (-0,29 %) CMB.TECH 14.580 € (-3,19 %) RECTICEL 10.720 € (+1,32 %) ASCENCIO 49.950 € (-1,09 %) BEKAERT 41.450 € (+2,47 %) MONTEA 67.000 € (+0,60 %) AGFA-GEVAERT 0.460 € (-0,43 %) ELIA GROUP 137.600 € (-0,51 %) BIOTALYS 2.880 € (-2,70 %) D'IETEREN GROUP 167.500 € (+2,13 %) SIPEF 95.200 € (+1,28 %) IBA 15.380 € (-1,03 %) NEXTENSA 46.000 € (+1,09 %) RETAIL ESTATES 70.000 € (+1,30 %) AGEAS 68.100 € (+0,52 %) KINEPOLIS GROUP 29.300 € (-1,84 %) EVS BROADC.EQUIPM. 31.150 € (-15,01 %)
RIBER 15.360 € (+16,54 %)
NN GROUP 75.840 € (+0,42 %)
RELX 28.380 € (-0,77 %)
VALLOUREC 24.040 € (-0,33 %)
DBV TECHNOLOGIES 3.182 € (-0,44 %)
WENDEL 88.900 € (+0,91 %)
DSM FIRMENICH AG 71.500 € (+0,25 %)
LVMH 472.600 € (-0,20 %)
STMICROELECTRONICS 57.930 € (+5,17 %)
OPMOBILITY 15.300 € (+2,20 %)
GECINA 72.350 € (-0,48 %)
AIR FRANCE -KLM 10.255 € (+1,64 %)
TIKEHAU CAPITAL 17.900 € (+2,52 %)
GTT 204.800 € (+0,59 %)
UNIBAIL-RODAMCO-WE 97.600 € (-0,06 %)
SAINT GOBAIN 75.280 € (+1,67 %)
ABN AMRO BANK N.V. 33.940 € (+1,65 %)
BASIC-FIT 29.900 € (-0,33 %)
COFACE 16.440 € (+0,80 %)
ADYEN 957.900 € (+1,58 %)
METROPOLE TV 11.500 € (-0,17 %)
CARREFOUR 17.090 € (-1,07 %)
IPSEN 160.200 € (-0,25 %)
SODEXO 45.640 € (+0,13 %)
AMUNDI 85.700 € (-0,12 %)
NOVACYT 0.580 € (+0,87 %)
ID LOGISTICS GROUP 362.500 € (-0,41 %)
ROCHE BOBOIS 25.600 € (-3,40 %)
ATOS 43.680 € (+7,22 %)
SES 8.950 € (+1,36 %)
2CRSI 46.700 € (+3,73 %)
NANOBIOTIX 36.460 € (+8,77 %)
AMG 38.640 € (+3,76 %)
FORVIA 10.375 € (+3,13 %)
SHELL PLC 37.110 € (-0,92 %)
AIRBUS 169.520 € (+2,15 %)
TRIGANO 153.600 € (-0,07 %)
BNP PARIBAS ACT.A 89.930 € (+0,86 %)
VIEL ET COMPAGNIE 18.900 € (+0,11 %)
ASR NEDERLAND 65.760 € (+1,20 %)
REMY COINTREAU 40.600 € (-0,93 %)
AALBERTS NV 38.760 € (+3,75 %)
VALEO 12.640 € (+2,39 %)
ABIVAX 105.900 € (+0,76 %)
VICAT 61.800 € (+1,98 %)
TOTALENERGIES 78.650 € (-2,01 %)
TELEPERFORMANCE 72.200 € (-1,45 %)
EKINOPS 3.100 € (+8,01 %)
ASML HOLDING 1 409.000 € (+4,74 %)
QUADIENT 12.340 € (+3,01 %)
MERCIALYS 11.960 € (0,00 %)
ALTEN 62.850 € (+1,05 %)
BILENDI 13.800 € (+0,29 %)
PHILIPS KON 23.370 € (+0,65 %)
CRCAM SUD R.A.CCI 245.500 € (+0,61 %)
AXA 40.120 € (+0,02 %)
KAUFMAN ET BROAD 25.050 € (+1,01 %)
WOLTERS KLUWER 62.500 € (-0,83 %)
DANONE 61.860 € (-1,59 %)
AHOLD DEL 36.650 € (-1,08 %) News Réglementées
|
04/05/2026 13:08
MEDICLIN increases group operating result in the first quarterEQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement PRESS RELEASE Q1 Report MEDICLIN increases group operating result in the first quarter
Offenburg, 4 May 2026 – MEDICLIN Aktiengesellschaft (Ticker: MED; WKN 659 510) achieved consolidated group revenue of EUR 186.9 million in the first three months of 2026 (previous year: EUR 176.9 million), representing an increase of EUR 10.0 million or 5.7%. Consolidated group operating result improved by EUR 4.1 million to EUR 9.3 million (previous year: EUR 5.2 million). “We can look back on a solid first quarter of 2026. This gives us confidence for the rest of the year,” said Tino Fritz, CFO of MEDICLIN, adding, “A stable occupancy rate and successful cost management are contributing to our financial success. We aim to achieve the same in the remaining three quarters of the year.” Reclassification To enhance transparency and comparability, a reclassification has been made in the income statement for 2026 and 2025. As a result, reported revenue has decreased, whilst other operating income has increased. Staff costs and purchased services are lower and are thus offset by higher other operating expenses. The reclassification has no impact on profit or loss. Development in the segments In the Post-acute segment, revenue of EUR 126.8 million was EUR 7.6 million, or 6.4%, higher than the previous year’s figure (previous year: EUR 119.1 million). The cost of materials ratio fell slightly to 19.6% (previous year: 21.9%). Absolute cost of materials was also 5.0% below the previous year’s figure at EUR 24.8 million (previous year: EUR 26.1 million). Staff costs increased by EUR 4.5 million, or 6.7%, compared with the same quarter of the previous year to EUR 72.2 million (previous year: EUR 67.7 million). The staff cost ratio rose slightly to 57.0% ( ; previous year: 56.9%). The operating result of the Post-Acute segment rose by EUR 4.8 million to EUR 9.7 million (previous year: EUR 4.9 million). Revenue for the Acute segment reached EUR 53.8 million (previous year: EUR 51.7 million). At EUR 16.1 million, cost of materials was EUR 0.5 million, or 3.2%, higher than in the same quarter of the previous year (previous year: EUR 15.6 million). The cost of materials ratio fell slightly to 30.0% (previous year: 30.3%). Staff costs amounted to EUR 34.9 million, an increase of 7.5% compared with the same quarter last year (previous year: EUR 32.5 million). The personnel expense ratio stood at 64.8%, compared with 62.9% in the same period of the previous year. Segment operating result fell by EUR 1.9 million to EUR -1.9 million due to the rise in expenses (previous year: EUR 0.0 million). Revenue in the Care segment rose to EUR 6.4 million in the first quarter of 2026 (previous year: EUR 6.1 million). The segment operating result of EUR 0.2 million was EUR 0.3 million higher than in the same period of the previous year (previous year: EUR -0.1 million). In the Service segment, services are reported under other income. These amounted to EUR 35.3 million, compared with EUR 35.1 million in the previous year. The Service segment achieved an operating result of EUR 1.3 million, compared with EUR 0.4 million in the same quarter of the previous year, representing an increase of EUR 0.9 million. Outlook The aforementioned adjustment to the presentation of the income statement does not result in any adjustment to the full-year forecasts. As the adjustment has no impact on profit or loss, the full-year forecast for operating result remains unaffected. Nor is an adjustment to the full-year forecast for consolidated group revenue necessary, as the relative growth rate remains unchanged due to the adjustment of the comparative year. At 5.7%, revenue growth in the first quarter of 2026 is within the forecast of 3.5% to 6.5% published in the 2025 Annual Report. The Management board is confident that the Group will achieve the revenue forecast for the 2026 financial year as well as the existing forecast for Group EBIT of between EUR 57.0 million and EUR 72.0 million. The interim report as at 31 March 2026 is available from today at www.mediclin.de in German and English. CONTACT Head of Investor Relations and Sustainability Ender Gülcan | T. +49 781488326 | ender.guelcan@mediclin.de MEDICLIN AG | Okenstraße 27 | 77625 Offenburg MEDICLIN Aktiengesellschaft is one of Germany’s leading healthcare providers, specialising in rehabilitation. MEDICLIN operates 31 clinics, six care homes and ten medical care centres across Germany. MEDICLIN employs around 9,900 staff and treats approximately 213,000 patients annually. Through a strong network, MEDICLIN offers integrated care from the initial doctor’s appointment through surgery and subsequent rehabilitation to outpatient aftercare. Medical and therapeutic staff, as well as nursing staff, work together in close coordination. MEDICLIN tailors the care and support provided to people in need of care to their individual needs and personal requirements. MEDICLIN is a company of the ASKLEPIOS Group. www.mediclin.de 04.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
2320632 04.05.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière